peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Cirrhosis
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Trial Timeline
Jun 1, 2006 → Jun 1, 2010
NCT ID
NCT00304551About peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin is a phase 3 stage product being developed by Chugai Pharmaceutical for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00304551. Target conditions include Liver Cirrhosis, Chronic Hepatitis C.
What happened to similar drugs?
20 of 20 similar drugs in Liver Cirrhosis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00304551 | Phase 3 | Completed |
Competing Products
20 competing products in Liver Cirrhosis